Rep. Cuellar Announces Lower Prescription Drug Costs

Dr. Cuellar Voted to Pass the Inflation Reduction Act (IRA), Which Enabled Negotiations to Lower Costs for Prescription Drugs Under Medicare

Translate to Spanish or other 102 languages!

Congressman Cuellar announced lower costs for the country’s most expensive prescription drugs under Medicare. Image for illustration purposes
Congressman Cuellar announced lower costs for the country’s most expensive prescription drugs under Medicare. Image for illustration purposes
- Advertisement -

Washington, DC – Congressman Cuellar announced lower costs for the country’s most expensive prescription drugs under Medicare.

“I voted to pass the IRA, which has lowered health care and prescription drug costs for Americans. It not only capped the monthly cost of insulin for seniors on Medicare at $35 but also limited out-of-pocket prescription drug costs for seniors,” said Dr. Cuellar, a senior member of the House Appropriations Committee. “Furthermore, due to the IRA, the administration was able to negotiate lower costs for ten of the most expensive prescription drugs under Medicare. This is a historic achievement and will bring needed relief to everyday Americans. I voted for the Inflation Reduction Act to ensure that Americans get the help they need. I will continue to support efforts to reduce health care costs.” 

The ten drugs negotiated down include Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, and NovoLog/Fiasp.

- Advertisement -

Through the IRA, more than 100,000 Texans on Medicare are saving on average $441 per year through the insulin price cap alone.  It caps insulin costs at $35 per month for those on Medicare and limits out-of-pocket prescription drug costs to $2,000 per year.

1,323,430 Texans will save $400 per year on average through the IRA’s $2,000 out-of-pocket cap, which will begin in 2025.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

Texas Adds New Condition to Mandatory Newborn Screening Tests

The Texas Department of State Health Services added a new enzyme deficiency test on June 1, 2026, to its newborn screening panel, meaning that all Texas newborns are now tested for 60 rare, genetic conditions. Tests for hearing loss and critical congenital heart disease are additional point-of-service tests typically conducted by the birthing center. 

Pancreatic Cancer Patients Gain Early Access to Experimental Drug Daraxonrasib Following Fast-Track FDA Decision

The U.S. Food and Drug Administration is announcing that it issued a “safe to proceed” letter to Revolution Medicines, allowing the sponsor to initiate an expanded access treatment protocol (EAP) for its experimental pancreatic cancer drug, daraxonrasib.

STHS GME Consortium Encourages Community to “Walk with a Doc”, June 6th

Mega Doctor News In an era defined by high-intensity workouts, wearable fitness trackers and advanced training techniques, one of simplest...

STHS Children’s Marks 20th Anniversary with Gala Honoring Pediatric Providers Behind Its Success

For the past 20 years, South Texas Health System Children’s has stood as a place where compassionate care and clinical excellence come together to create hope for children and their families.
- Advertisement -